VRCA Q3'26 Earnings: revenue estimate is 6.20M USD

What happened

Verrica Pharmaceuticals is scheduled to announce its Q3'26 results on November 09, with disclosure expected at 7:00 AM ET. The supplied estimate is revenue of 6.20M USD and earnings per share, or profit or loss per share, of (0.50) USD.

Confirmed

Global impact / market context

The results will show whether revenue and loss per share matched the estimates, giving investors information about the company’s recent sales and costs. Revenue below the estimate could indicate weaker sales than expected, while a larger loss could raise questions about spending and cash available.

Analyst inference

The article lists prior quarterly revenue estimates and reported results, with reported revenue above estimates in each of the four quarters shown. That history offers context, but does not establish that Q3'26 will meet or exceed its estimate.

Analyst inference

What to watch

1. Compare announced Q3'26 revenue with the 6.20M USD estimate; the gap would show whether sales were stronger or weaker than the forecast. Analyst inference
2. Compare earnings per share with the anticipated (0.50) USD; earnings per share means profit or loss allocated to each share. Analyst inference
3. Check the announcement time and reported figures: the article gives November 09 and 7:00 AM ET as expected disclosure details, not confirmed results. Confirmed

Evidence

• Original source link unavailable